Published results from Rx Activate member population
Reducing GLP-1 spend while driving meaningful weight loss
$403PMPMestimated pharmacy savings
Members were guided to the most appropriate care path, whether behavior change alone, GLP-1s, or lower-cost anti-obesity medications (AOMs).
Managing rising GLP-1 costs with smarter, coordinated care
With GLP-1 spend reaching over $70 billion without consistent clinical oversight, employers face growing pressure to manage cost and outcomes. Vida and Capital Rx deliver a coordinated solution that pairs personalized care with Judi®-driven medication management to promote behavior change and appropriate use of GLP-1s.
Members achieved sustained weight loss with and without GLP-1s
> 11.6%
weight loss at
12 months (GLP-1s)
> 6.0%
weight loss at 12 months (Behavior change and/or low-cost medication)*
*clinically significant weight loss is > 5%
High engagement without medication dependence
- Members participated in 39 lifestyle activities/month on average
- Over ~10 months of participation
Mooney K, Munro C, Voelker L, Venkatesan A. The impact of Capital Rx’s Rx Activate program in partnership with Vida on GLP-1 and anti-obesity medication utilization, weight loss, and inferred cost avoidance. AMCP Annual Meeting; 2026.
Rx Activate member spotlight: Adam’s results
↓ 30 lbs (–12.7% body weight)
↓ 2.2 A1C points
Achieved through personalized coaching, nutrition support, and consistent engagement.
